Les anticorps monoclonaux (AcM) ont été utilisés pour traiter des cancers dès le début des années 1980, en particulier lors du travail pionnier de l’équipe de Ronald Levy dans le traitement des lymphomes. Ces traitements ont pendant longtemps été considérés comme une sérothérapie passive à effet immédiat et à court terme. Cependant, au cours de ces dernières années, le concept d’un effet « vaccinal » des anticorps à usage thérapeutique en oncologie a peu à peu vu le jour du fait de réponses cliniques à long terme observées chez certains patients et de différentes études précliniques. En 2010, notre équipe a démontré que des souris immunocompétentes injectées avec les cellules tumorales EL4-huCD20 et traitées avec un AcM anti-huCD20 générait une réponse immunitaire anti-tumorale à long-terme par le biais de mécanismes dépendants de la région constante de l’anticorps et de lymphocytes T CD4+. Mon travail de thèse a donc porté sur l’analyse des mécanismes cellulaires et moléculaires par lesquels le traitement par un AcM anti-CD20 génère une immunité cellulaire adaptative anti-tumorale. J’ai ainsi pu montrer que le traitement des souris avec l’AcM anti-CD20 conduit à une expansion de lymphocytes Th1 producteurs d’IFN-γ, à l’apparition de lymphocytes T CD4+ effecteurs mémoires spécifiques des cellules tumorales CD20+, et au blocage de l’expansion de lymphocytes Tregs induite par les cellules tumorales. Le rôle central dans la protection anti-tumorale et la genèse d’une réponse adaptative anti-tumorale joué par l’axe IL-12/IFN-γ et leurs principales sources cellulaires, cellules dendritiques (DCs) et cellules NK, a été démontré par des expériences de neutralisation de ces cytokines, qui provoque une importante diminution du nombre de Th1 spléniques, de déplétion des cellules NK, ainsi que par des analyses phénotypiques qui ont permis d’identifier des DCs activées par le traitement - comme le montre l’expression accrue des molécules de classe II du CMH et de co-stimulation CD80 et CD86 - comme une importante source cellulaire de l’IL-12. Enfin, nous avons pu montrer qu’un variant de l’IL-2, liant préférentiellement le récepteur de l’IL-2By et faiblement le récepteur de l’IL-2aBy exprimé majoritairement par les Tregs, permettait l’obtention d’une protection anti-tumorale accrue d’animaux porteurs de tumeurs et traités par l’AcM anti-CD20. En conclusion, nous avons démontré qu’un contexte immunitaire pro-tumoral façonné par la présence d’une tumeur en développement peut être inversé par le traitement par un anticorps anti-tumoral, aboutissant à un contexte anti-tumoral. Qu’une telle réponse immunitaire adaptative cellulaire puisse être observée chez des patients atteints de lymphomes, traités par un anticorps anti-CD20, reste encore à être déterminé. / Monoclonal antibodies have been used to treat cancers since the early 1980s, in particular with the pioneer work of Ronald Levy for the treatment of lymphomas. Those treatments have been considered for a long time as a passive serotherapy with immediate and short term actions. Yet, recently, the idea of a vaccine effect of therapeutic antibodies in oncology have appeared, after preclinical studies and clinic observations suggesting a long term immune response in patients. In 2010, our team demonstrated that immunocompetent mice injected with EL4-huCD20 tumor cells and treated with anti-huCD20 monoclonal antibody generated a long term anti-tumor immune response linked with mechanisms dependent on constant part of antibodies and CD4+ T cells. My PhD work was based on the analysis of cellular and molecular mechanisms by which the treatment by an anti-CD20 mAb generates a cellar adaptive anti-tumor immunity. I could show that the treatment of mice with anti-CD20 antibody lead to the expansion of Th1 lymphocytes IFN-γ producers, to the apparition of effector memory CD4+ T cells specific for CD20 antigen, and to the blockade of the expansion of Treg cells induced by tumor cells. The key role of an adaptive anti-tumor immune response played by IL-12/IFN- γ and their main cellular sources, dendritic cells and NK cells, in the anti-tumor protection and genesis, has been demonstrated by experiments of cytokine neutralization, provoking an important decrease of splenic Th1 number, by NK depletion and by phenotypic analysis that allowed the identification of DCs activated by the treatment – as it is shown by the increased expression of MHC-II and CD80 and CD86 costimulation molecules, - as an important cellular source of IL-12. Finally, we could show that a variant of IL-2, binding preferentially IL-2By with a lower affinity for the IL-2aBy receptor mainly expressed by Tregs, could induce an increased anti-tumor protection of tumor-bearing animals treated with anti-CD20 mAb. In conclusion, we have demonstrated that a pro-tumor immune contexture affected by a growing tumor can be modified by an anti-tumor antibody leading to an anti-tumor contexture. That such cellular adaptive immune response could be observed in lymphoma patients treated with anti-CD20 still need to be determined.

Les anticorps monoclonaux (AcM) ont été utilisés pour traiter des cancers dès le début des années 1980, en particulier lors du travail pionnier de l’équipe de Ronald Levy dans le traitement des lymphomes. Ces traitements ont pendant longtemps été considérés comme une sérothérapie passive à effet immédiat et à court terme. Cependant, au cours de ces dernières années, le concept d’un effet « vaccinal » des anticorps à usage thérapeutique en oncologie a peu à peu vu le jour du fait de réponses cliniques à long terme observées chez certains patients et de différentes études précliniques. En 2010, notre équipe a démontré que des souris immunocompétentes injectées avec les cellules tumorales EL4-huCD20 et traitées avec un AcM anti-huCD20 générait une réponse immunitaire anti-tumorale à long-terme par le biais de mécanismes dépendants de la région constante de l’anticorps et de lymphocytes T CD4+. Mon travail de thèse a donc porté sur l’analyse des mécanismes cellulaires et moléculaires par lesquels le traitement par un AcM anti-CD20 génère une immunité cellulaire adaptative anti-tumorale. J’ai ainsi pu montrer que le traitement des souris avec l’AcM anti-CD20 conduit à une expansion de lymphocytes Th1 producteurs d’IFN-γ, à l’apparition de lymphocytes T CD4+ effecteurs mémoires spécifiques des cellules tumorales CD20+, et au blocage de l’expansion de lymphocytes Tregs induite par les cellules tumorales. Le rôle central dans la protection anti-tumorale et la genèse d’une réponse adaptative anti-tumorale joué par l’axe IL-12/IFN-γ et leurs principales sources cellulaires, cellules dendritiques (DCs) et cellules NK, a été démontré par des expériences de neutralisation de ces cytokines, qui provoque une importante diminution du nombre de Th1 spléniques, de déplétion des cellules NK, ainsi que par des analyses phénotypiques qui ont permis d’identifier des DCs activées par le traitement - comme le montre l’expression accrue des molécules de classe II du CMH et de co-stimulation CD80 et CD86 - comme une importante source cellulaire de l’IL-12. Enfin, nous avons pu montrer qu’un variant de l’IL-2, liant préférentiellement le récepteur de l’IL-2By et faiblement le récepteur de l’IL-2aBy exprimé majoritairement par les Tregs, permettait l’obtention d’une protection anti-tumorale accrue d’animaux porteurs de tumeurs et traités par l’AcM anti-CD20. En conclusion, nous avons démontré qu’un contexte immunitaire pro-tumoral façonné par la présence d’une tumeur en développement peut être inversé par le traitement par un anticorps anti-tumoral, aboutissant à un contexte anti-tumoral. Qu’une telle réponse immunitaire adaptative cellulaire puisse être observée chez des patients atteints de lymphomes, traités par un anticorps anti-CD20, reste encore à être déterminé. / Monoclonal antibodies have been used to treat cancers since the early 1980s, in particular with the pioneer work of Ronald Levy for the treatment of lymphomas. Those treatments have been considered for a long time as a passive serotherapy with immediate and short term actions. Yet, recently, the idea of a vaccine effect of therapeutic antibodies in oncology have appeared, after preclinical studies and clinic observations suggesting a long term immune response in patients. In 2010, our team demonstrated that immunocompetent mice injected with EL4-huCD20 tumor cells and treated with anti-huCD20 monoclonal antibody generated a long term anti-tumor immune response linked with mechanisms dependent on constant part of antibodies and CD4+ T cells. My PhD work was based on the analysis of cellular and molecular mechanisms by which the treatment by an anti-CD20 mAb generates a cellar adaptive anti-tumor immunity. I could show that the treatment of mice with anti-CD20 antibody lead to the expansion of Th1 lymphocytes IFN-γ producers, to the apparition of effector memory CD4+ T cells specific for CD20 antigen, and to the blockade of the expansion of Treg cells induced by tumor cells. The key role of an adaptive anti-tumor immune response played by IL-12/IFN- γ and their main cellular sources, dendritic cells and NK cells, in the anti-tumor protection and genesis, has been demonstrated by experiments of cytokine neutralization, provoking an important decrease of splenic Th1 number, by NK depletion and by phenotypic analysis that allowed the identification of DCs activated by the treatment – as it is shown by the increased expression of MHC-II and CD80 and CD86 costimulation molecules, - as an important cellular source of IL-12. Finally, we could show that a variant of IL-2, binding preferentially IL-2By with a lower affinity for the IL-2aBy receptor mainly expressed by Tregs, could induce an increased anti-tumor protection of tumor-bearing animals treated with anti-CD20 mAb. In conclusion, we have demonstrated that a pro-tumor immune contexture affected by a growing tumor can be modified by an anti-tumor antibody leading to an anti-tumor contexture. That such cellular adaptive immune response could be observed in lymphoma patients treated with anti-CD20 still need to be determined.

Die Invasion von Leukozyten in das zentrale Nervensystem (ZNS) ist ein wesentlicher Bestandteil bei der Pathogenese von Hirnverletzungen sowie akuten und chronischen Entzündungsvorgängen im Gehirn. Mikrogliazellen, die überwiegende Population immunkompetenter Zellen des ZNS, stellen die erste Verteidigungslinie im Hinblick auf Verletzungen und Erkrankungen des Gehirns dar. Im Rahmen vieler neurodegenerativer Erkrankungen wird die Zerstörung von Neuronen, aber auch die kollaterale Gewebsschädigung auf die Aktivierung der Mikrogliazellen zurückgeführt. Die vorliegende Arbeit beschreibt erstmalig einen regulatorischen Aktivierungszustand der Mikroglia (CD40dimCD86dimIL-10high), der zur Induktion regulatorischer Foxp3+ T-Zellen (Treg) führt. Die Stabilität und funktionelle Aktivität Mikroglia-induzierter Treg konnte sowohl in vitro als auch in vivo gezeigt werden. In vitro inhibierten sie die Proliferation antigen-spezifischer Effektorzellen, in vivo führte ein adoptiver Transfer der regulatorischen T-Zellen zur Abmilderung des Krankheitsverlaufes experimentell induzierter, autoimmuner Enzephalomyelitis (EAE). Mikrogliazellen unterstützten sowohl die Proliferation bereits ausgebildeter regulatorischer T-Zellen als auch deren Differenzierung aus naiven T-Zellen. Die Induktion regulatorischer T-Zellen durch Mikroglia war Major Histocompatibility Complex (MHC)-II-abhängig und antigenspezifisch. Für Untersuchungen zur in vivo Relevanz wurden MHC-II-chimäre Mäuse generiert und eine Läsion im entorhinalen Kortex gesetzt. Fehlte MHC-II in ZNS-residenten Zellen, wurden weniger regulatorische T-Zellen pro Leukozyt in die lädierten Hemispheren rekrutiert. Zusammenfassend demonstrieren diese Ergebnisse das Modulationspotential von Mikrogliazellen auf die CD4+ T-Zellantwort. Die Mikroglia-induzierte Differenzierung und Proliferation von Foxp3+ regulatorischen T-Zellen ist ein möglicher Mechanismus der Regulation von Entzündungsvorgängen im ZNS durch Mikrogliazellen. / The invasion of leukocytes into the central nervous system (CNS) is a key event in the pathogenesis of CNS injury and acute or chronic inflammatory neurological diseases. However, regulatory mechanisms of local innate immune responses that limit CNS inflammation are only poorly understood. Microglia are the predominant innate immune cells of the brain and present the first line of defence in CNS injury or disease. In the context of neurodegenerative disease, microglia activation accounts for collateral tissue damage and neurodestruction. This thesis for the first time describes a regulatory microglia phenotype (MHCII+CD40dimCD86dimIL-10high) that induced a strong Foxp3+ regulatory T cell (Treg) response. Microglia-induced Treg cells were stable and functionally active in vitro by inhibiting antigen-specific proliferation of effector T cells and in vivo, by attenuating experimental autoimmune encephalomyelitis (EAE) disease course after adoptive transfer. The data also suggested that regulatory microglia can mediate both, proliferation of Foxp3+ Treg cells and de novo differentiation from naive CD4+ T cells. Microglia-mediated Treg induction was proven to be MHCII and antigen-dependent. Using entorhinal cortex lesion (ECL) as a brain injury mouse model, diminished Foxp3+ Treg cell recruitment per infiltrated leukocyte in chimeric mice lacking MHCII specifically in the CNS was demonstrated, indicating in vivo relevance of antigen presentation by brain resident cells. Taken together, these findings demonstrate that microglial cells can directly modulate CD4+ T cell responses by regulating molecule levels for efficient antigen presentation and levels of secreted cytokines and chemokines. Microglia-mediated differentiation and proliferation of Foxp3+ Treg cells can be one of the mechanisms how microglia contribute to local immune homeostasis and limit CNS inflammation.

Submitted by JÚLIO HEBER SILVA (julioheber@yahoo.com.br) on 2016-12-19T17:52:15Z No. of bitstreams: 2 Tese - Maurício Barcelos Costa - 2014.pdf: 740997 bytes, checksum: fec1f12612ff6a41fbbbee9640600a35 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Rejected by Luciana Ferreira (lucgeral@gmail.com), reason: Júlio, falta o arquivo da tese. on 2016-12-26T12:31:54Z (GMT) / Submitted by JÚLIO HEBER SILVA (julioheber@yahoo.com.br) on 2017-01-02T15:41:57Z No. of bitstreams: 2 Tese - Maurício Barcelos Costa - 2014.pdf: 10731375 bytes, checksum: d59433128feb9bc7facacb81cb311a98 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-01-03T09:40:55Z (GMT) No. of bitstreams: 2 Tese - Maurício Barcelos Costa - 2014.pdf: 10731375 bytes, checksum: d59433128feb9bc7facacb81cb311a98 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2017-01-03T09:40:55Z (GMT). No. of bitstreams: 2 Tese - Maurício Barcelos Costa - 2014.pdf: 10731375 bytes, checksum: d59433128feb9bc7facacb81cb311a98 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2014-02-26 / Leprosy is a complex, chronic, infectious dermato-neurological disease that affects the skin and peripheral nerves especially during acute immune-inflammatory episodes known as type 1/T1R and type 2/T2R reactions. There is no experimental model for leprosy and leprosy skin lesions have been extensively used to unravel its multifaceted immunopathological mechanisms.This study investigated in situ expression of two distinct cell populations with important immunoregulatory roles: T regulatory (Treg) cells and mast cells (MC) in diverse skin diseases with emphasis on leprosy T1R and T2R. For the Treg cell study, 154 skin biopsies from 114 participants belonging to 3 groups were investigated: 1. Leprosy (n=74), 56 T1R (28-paired biopsies reactionfree/reactional from the same patient, 28 single reactional biopsy), 18 T2R (12 pairedreaction-free/reactional lesions, 6 single reactional biopsy); 2. Dermatoses: (n=29) noninfectious and cutaneous infectious diseases; 3. Normal controls: skin fragment of mammoplasty from healthy females that had cosmetic surgery. Double immunohistochemical detection of Treg cells was performed with automated platform for CD25 and Foxp3 staining. Quantifications of double immunostained Treg cells was performed (values expressed by mm2 ) blinded to the participants’ clinical status. For the mast cell study 80 skin biopsies from 3 groups were investigated: 40 newly diagnosed untreated leprosy patients (18 reaction-free, 11 T1R, 11 T2R), 29 patients with other dermatoses (the same as for Treg study) and 11 normal skins. Toluidine blue stained intact and degranulated MC counts/mm2 ; streptavidin-biotin-peroxidase immunostaining was used to detect tryptase/try+ and chymase/chy+ MCs and their density (median optical density) was evaluated. Results: Treg study: Not one CD25+ Foxp3+ Treg cell was seen in any of the 11 normal skin sections while variable numbers were detected in skin diseases (p<0.0001); the number of double stained cells was higher in infectious compared to non-infectious diseases (p=0.008). Treg cell numbers were comparable between leprosy and other infectious dermatoses (p=0.157) Treg cell counts in reactional lesions were higher than in reaction-free leprosy lesions (p<0.002). Paired biopsies of T1R or T2R reactional/reaction-free lesions showed xxvii increased numbers of Treg during T1R compared to reaction-free lesions from the same patient (p< 0.001). Treg cell median in T1R developed during MDT was slightly higher compared to T1R developed at diagnosis in naïve patients (p=0.047). There was a trend in increasing Treg cell numbers from the tuberculoid to borderline-lepromatous form, which showed the highest median value of Tregs, however this difference was not significant (p>0.8). Mast cell study: Infectious and non-infectious skin lesions showed higher numbers of degranulated than intact MC both for leprosy and other dermatoses, compared to normal skin. The numbers of degranulated MC were higher than intact MC regardless of the leprosy form (from tuberculoid/TT to lepromatous/LL), regardless of the occurrence of leprosy reactions (reactional and reaction-free) and regardless of the type of reaction (T1R/T2R). Try+ MC numbers and density were higher than chy+ MC in leprosy, in reaction-free and reactional lesions, particularly in T2R, but not in other dermatoses. Conclusions: Higher Treg numbers seen in T1R suggest Treg role in suppressing the exacerbated cell-mediated phenomenon that causes T1R. Differential expression/ of try+ and chy+ MC subsets was seen in leprosy compared to other skin diseases and to normal skin. However, neither leprosy form nor leprosy reaction was associated with MC changes in lesions suggesting that the Mycobacterium leprae infectious process per se dictates MC expression in leprosy skin lesions. / A hanseníase é uma complexa doença dermato-neurológica, crônica, de causa infecciosa que afeta a pele e os nervos periféricos, especialmente durante os episódios imunoinflamatórios agudos conhecidos com reações tipo 1/RT1 e tipo 2/RT2. Não existe modelo experimental para hanseníase e as lesões de pele têm sido extensivamente usadas para desvendar os multifacetados mecanismos imunopatológicos associados com a doença. Este estudo investigou a expressão in situ de duas distintas populações celulares que apresentam importante papel imunorregulatório: células Treg (Treg) e mastócitos (MC) em pele normal e diversas doenças cutâneas com ênfase nas reações hansênicas RT1 e RT2. Para o estudo de Tregs foram utilizadas 154 biópsias cutâneas de 114 participantes de três grupos: 1. Hanseníase (n=74), 56 RT1 (28-biópsias pareadas do mesmo paciente sem reação/durante reação, 28 biópsias únicas de RT1), 18 RT2 (12 biópsias pareadas sem reação/durante reação, 6 biópsias únicas de RT2); 2. Dermatoses: (n=29) doenças cutâneas não infecciosas e infecciosas. Controles Normais: fragmentos de peles obtidos de mamoplastias eletivas em mulheres saudáveis. Imunomarcação dupla CD25+ Foxp3+ de células Treg foi realizada em plataforma automatizada. Quantificação das células Treg duplo positivas foram feitas sem conhecimento da condição clínica do paciente (valores expressos em mm2 ). Para o estudo dos MC 80 biópsias de 3 grupos foram investigadas: 40 pacientes com hanseníase recém diagnosticados não tratados (18 sem reação, 11 RT1, 11 RT2), 29 pacientes com outras dermatoses e 11 biópsias de pele normal. Quantificação de MC intactos e desgranulados corados por azul de toluidina/mm2 ; imunomarcação streptavidina-biotina-peroxidase foi empregada para detectar MC triptase/try+ e chimase/chy+ e a densidade ótica (mediana da densidade ótica) foi avaliada. Resultados: Estudo das Tregs: Nenhuma célula Treg CD25+ Foxp3+ foi identificada em nenhuma das 11 amostras de pele normal, enquanto um número variável de Tregs foi identificado nas diversas doenças cutâneas (p<0.0001); o número de células Treg duplo positivas foi maior nas doenças infecciosas comparado com as não-infecciosas (p=0.008). Medianas de Treg entre hanseníase e outras doenças infecciosas foram semelhantes (p=0.157). Quantificação de Tregs em lesões reacionais foram maiores do que as sem reação (p<0.02). Nas biópsias pareadas de lesões de xxv RT1/sem reação ou RT2/sem reação, números maiores de Treg foram vistos durante a RT1 quando comparados com a não reacional do mesmo paciente (p< 0.001). Mediana de Treg em RT1 desenvolvidas durante MDT foi ligeiramente superior comparada a RT1 desenvolvida em pacientes sem de tratamento (p=0.047). Observou-se uma tendência de aumento no número das Tregs do polo tuberculoide em direção ao lepromatoso, mais especificamente até a forma borderline-lepromatosa que apresentou a maior mediana da quantificação de Treg, entretanto esta diferença não foi estatisticamente significativa (p>0.8). Estudo dos Mastócitos: lesões cutâneas de origem infecciosa e não infecciosa mostraram números aumentados de mastócitos desgranulados do que intactos tanto na hanseníase como nas outras dermatoses quando comparados com pele normal. Os números de mastócitos (MC) desgranulados foram maiores do que intactos, independente da forma de hanseníase (do polo tuberculoide/TT ao lepromatoso/LL), independente da ocorrência de reações hansênicas (lesão reacional/sem reação) e independente do tipo de reação (RT1/RT2). Número e densidade de mastócito triptase positivo (MC try+ ) estão aumentados em relação aos quimase positivo (MC chy+ ) na hanseníase, em pacientes com e sem reação, particularmente na RT2, mas não nas outras dermatoses. Conclusões: aumento nas Treg detectados durante RT1 sugerem papel supressor dessas células em eventos associados à resposta imune celular exacerbada, responsáveis pela RT1. Expressão diferencial das subpopulações de MC try+ e chy+ foi observada na hanseníase em relação a outras doenças cutâneas e pele normal. Entretanto, nem a forma da hanseníase, nem a ocorrência de reação hansênica, estava associada a mudanças nas subpopulações de MC nas lesões sugerindo que o processo infeccioso pelo Mycobacterium leprae per se direciona a expressão de MC nas lesões cutâneas da hanseníase.

Les facteurs de transcription Eos et Helios ont été décrits comme étant des modulateurs des fonctions des cellules T régulatrices (Treg). Nos résultats suggèrent qu’Eos et Helios ne sont pas nécessaires, ni pour la différenciation, ni pour les principales fonctions des cellules Treg CD4+. Cependant, les cellules Helios-/- présentent une meilleure activité suppressive et à un profil transcriptomique de cellules Treg activées. Pour tester si Eos et Helios coopèrent pour réguler les fonctions des cellules Treg, nous avons analysé les souris doubles mutantes. Nos découvertes indiquent que la perte combinée d’Eos et d’Helios n’a pas d’effet sur la biologie des cellules Treg. De plus, nous avons montré qu’Eos et Helios sont induits dans les cellules Treg CD8+. Néanmoins, seule la perte d’Helios ou celle combinée d’Eos et d’Helios affectent leur différenciation. Tous ces résultats suggèrent donc qu’Eos et Helios ne sont pas requis pour réguler les fonctions essentielles des cellules Treg. / The transcription factors Eos and Helios have been described as modulators of regulatory T cell (Treg) functions. Our results suggest that they are not necessary for the differentiation and essential functions of CD4+ Treg cells. However, Helios-/- cells present a superior suppressive activity and a transcriptional profile of activated Treg cells. To test if Eos and Helios can cooperate to regulate Treg cell functions, we then analyzed double null mice. Our findings indicate that loss of both Eos and Helios has no effect on Treg cell biology during homeostasis. In addition, we showed that Eos and Helios are induced in CD8+ Treg cells. However, only loss of Helios, or both Helios and Eos, affect their differentiation. Altogether, these results suggest that Eos and Helios are not required regulate essential CD4+ Treg cell functions, but the absence of Helios may have an impact on their level of activation. Finally, Helios and Eos may play role of in the CD8+ Treg cell compartment.

Les antibiotiques (ATB) inhibent l'efficacité anti-tumorale du blocage de PD1, mais les mécanismes sous-jacents à leurs effets immunosuppresseurs demeurent inconnus. Nous montrons ici que les ATB favorisent l'accumulation des cellules T FoxP3+ et RORct+ a4b7hi dans les ganglions lymphatiques et les lésions tumorales. Les ATB induisent la perte de l'adressine MadCAM-1 iléale provoquant la recirculation des lymphocytes T régulateurs et TH17 α4β7hi de l’iléon vers le microenvironnement tumoral (TME). Cette migration a été visualisée grâce à 2 méthodes, la première consiste en l’ injection directe de carboxyfluoresceine succinimidyl ester (CFSE) dans les ganglions lymphatiques mésentériques des souris porteuses de tumeurs, l’autre utilise des souris transgéniques Kaede contenant une protéine flurorescente photoconvertible. Les hétérodimères d'adressine MAdCAM-1 et d'intégrine α4β7 sont indispensables pour l'efficacité anti-tumorale et dans l'immuno-surveillance induite par les anticorps anti-PD1. L’utilisation de modèles knock-out de MadCAM-1 ou d’ anticorps bloquant son ligand α4β7, compromettent l’efficacité anticancéreuse du blocage du PD1 ceci en mobilisant les cellules entérotropes α4β7hi Treg et TH17 vers le TME et inversement, en réduisant le retour du Treg du TME vers l'intestin. L’inhibition de la voie MadCAM-1 au niveau iléal réduit simultanément les lymphocytes CCR5+ effecteurs et mémoires dans le tissu tumoral. Ces résultats démontrent l’existence d’un lien mécanistique entre la dysbiose intestinale et l'efficacité du traitement anti- tumoral, l’importance de l'axe intestin-tumeur dans l’ immunosurveillance du cancer et ouvre des perspectives d’application clinique pour cibler la voie MAdCAM-1 α4β7+ . / Antibiotics (ATB) inhibit the anticancer efficacy of PD1 blockade but the mechanisms underlying their immunosuppressive effects remains unknown. Here we show that ATB promote the accumulation of enterotropic, ileum egressing FoxP3+ and RORct+ α4β7 hi T cells into tumor draining lymph nodes and tumor lesions. ATB induce the loss of ileal MadCAM-1 adressin provoking the recirculation of α4β7 hi ileal Treg and TH17 cells to the tumor microenvironment (TME), as visualized using direct injection of carboxyfluorescein succinimidyl ester in mesenteric lymph nodes of tumor bearers as well as Kaede transgenic mice harboring a photoconvertible flurorescent protein. MAdCAM-1 addressin and α4β7 integrin heterodimers are indispensable for the anticancer efficacy and the immuno-surveillanc elicited by anti-PD1 antibodies. Gene defects in MadCAM-1 as well as antibodies blocking its ligand α4β7, severely compromise the anticancer effects of PD1 blockade by mobilizing enterotropic α4β7hi Treg and TH17 cells towards the TME and conversely reducing Treg homing from the TME to the gut, concomitantly reducing CCR5+ effector memory tumor infiltrating lymphocytes. These findings demonstrate a mechanistic link between gut dysbiosis and tumor treatment efficacy and unveil the potential clinical relevance of the MAdCAM-1 α4β7+ and the gut-tumor axis in cancer immunosurveillance.

Parasitische Nematoden beeinflussen gezielt die Abwehrreaktionen ihres Wirtes. Dies wird besonders während der chronischen Infektionsphase durch eine herabregulierte T-Zell-Antwort auf Parasitenantigene und andere Stimuli ersichtlich. In dieser Arbeit wurde die T-Zell-Antwort gegen einen intestinalen Nematoden untersucht. Mäuse wurden mit dem Trichostrongyliden Heligmosomoides polygyrus infiziert und in der Folge Effektor- sowie regulatorische T-Zellen (Tregs) untersucht. Subpopulationen von CD4+ T-Zellen wurden aus chronisch infizierten Mäusen isoliert und in naive Empfänger transferiert, welche nachfolgend infiziert wurden. Dabei zeigte sich, dass der Transfer von CD4+ Effektor-T-Zellen zu einer verminderten Wurmlast in den Empfängertieren führte, diese Zellen also einen partiellen Schutz gegen die Primärinfektion vermitteln. Der gleichzeitige Transfer von Tregs beeinflusste diesen Effekt nicht. Tregs allein zeigten keinerlei Einfluss auf die Wurmlast der Empfänger. Die Protektion durch Transfer von Effektor-T-Zellen kann vermutlich auf eine kleine Antigen-spezifische Population von CD4+ Zellen zurückgeführt werden. Diese Zellen wurden durch die Expression von CD40-L (CD154) nach Restimulation mit Parasitenantigen in vitro charakterisiert und enthielten einen Großteil der Zytokinproduzenten unter den CD4+ Zellen. Während diese Effektorzellen ein deutliches Th2-Zytokinprofil durch Produktion von Interleukin-4 (IL-4) und IL-13 zeigten, reagierte eine Treg-Subpopulation mit der Sekretion hoher Mengen von IL-10 auf Antigenstimulation. Diese Tregs waren durch Expression des Integrins AlphaE (CD103)Beta7 sowie CD25 und Foxp3 charakterisiert und vermittelten in vitro die stärkste Suppression anderer T-Zellen, wenn sie aus chronisch infizierten Mäusen isoliert wurden. Durch Untersuchung der zellulären Zusammensetzung von mesenterialen Lymphknoten und Milz konnte gezeigt werden, dass die Frequenz solcher regulatorischer Zellen im Verlauf der Infektion dauerhaft und überproportional zunimmt. Im Gegensatz dazu wurde am Infektionsort nur eine vorübergehende Akkumulation von Tregs (Foxp3+) während der akuten Phase der Infektion nachgewiesen. Diese Ergebnisse zeigen den Einfluss einer intestinalen Nematodeninfektion auf die Aktivität von Tregs und das Potential parasitenspezifischer CD4+ Effektor-Zellen zur Vermittlung von Schutz gegen die Infektion. Ein weiteres Projekt dieser Arbeit wahr die Verabreichung eines immunmodulatorischen Parasitenproteins, des Filariencystatins Av17, in einem Mausmodell entzündlicher Darmerkrankungen. In Mäusen wurde eine kolitisartige Entzündung durch eine Chemikalie im Trinkwasser induziert. Die regelmäßige Verabreichung von rekombinant exprimiertem Cystatin verminderte die Entzündungsreaktion signifikant. Damit konnte in dieser Arbeit gezeigt werden. dass Entzündungsreaktionen, die nicht durch den Parasiten selbst hervorgerufen werden, durch die Applikation einer einzelnen Parasitenkomponente unterdrückt werden können. / Parasitic nematodes specifically modulate the immune response of their hosts. A cellular hyperreactivity, especially during the chronic phase of infection, is a distinct finding of such infections. The T cell response against an intestinal nematode was analyzed in this work. Mice were infected with the trichostrongylid Heligmosomoides polygyrus and surveyed for changes concerning effector and regulatory T cells (Tregs). Subpopulations of CD4+ T cells were isolated from chronically infected mice and adoptively transferred to naive recipients, which were subsequently infected. The Transfer of CD4+ effector cells conferred partial protection, seen as decreased worm burdens in recipients. This effect was unimpaired by simultaneous transfer of Tregs. The transfer of purified Tregs alone showed no effect on worm burdens. The protection by transfer of effector T cells was probably due to a small parasite-specific population, which was characterized by the expression of CD40-L (CD154) after antigen-restimulation. The CD154+ population contained high frequencies of cells reacting with production of the Th2 key cytokines interleukin-4 (IL-4) and IL-13. On the other hand, a subpopulation of Tregs secreted high amounts of IL-10 in response to the antigen. These Tregs were characterized by the expression of the integrin AlphaE (CD103)Beta7, as well as CD25 and Foxp3. They showed a peculiar strong suppressive efficacy on the proliferation of other T cells, especially when derived from chronically infected donors. Analyzing the cellular composition of mesenteric lymph nodes and spleens in response revealed a lasting and over-proportional increase in frequencies of these Tregs. In clear contrast, only a transient increase of Foxp3-expressing Tregs was detected at the site of infection during the acute phase. These results point out the changes Treg activity during an intestinal nematode infection and show the potential of CD4+ effector cells in mediating protection against infection. A second project of this work was the application of an immunomodulatory parasite protein, the filarial cystatin Av17, in a mouse model of inflammatory bowel disease. Mice developed an inflammatory response to a chemical applied in the drinking water. The repeated application of recombinantly expressed cystatin significantly diminished the inflammatory response. Hence, this work showed the potential of a single parasite component in suppressing inflammatory processes not caused by the parasite itself.

Les lymphocytes T régulateurs (Treg) jouent un rôle prépondérant dans la tolérance du système immunitaire. En physiopathologie, un défaut quantitatif ou fonctionnel en Treg favorise le développement de maladies auto-immunes tandis que leur présence participe au développement tumoral. En particulier, la présence de Treg dans le stroma immunitaire de la tumeur (TiTreg) est de mauvais pronostic pour la survie des patientes atteintes de cancers du sein et de l'ovaire. Les Treg sont recrutés dans la tumeur via l'axe CCL22/CCR4 et sont activés et amplifiés via leur interaction avec les pDC et l'axe de co-stimulation ICOS-ICOSL qui favorise leurs capacités suppressives. Ce projet contribue aux efforts réalisés ces dernières années visant à la compréhension des mécanismes d'immunosuppression des Treg opérant dans les tumeurs humaines. En effet, ce projet met en évidence que les Ti-Treg humains expriment fortement l'ectonucléotidase membranaire CD39. Cette enzyme extracellulaire catabolise l'Adénosine tri-phosphate (ATP) en Adénosine Monophosphate (AMP) pouvant être ensuite dégradé, via l'ectonucléotidase CD73, en Adénosine (Ado). Alors que l'ATP représente une Alarmine (signal de danger extracellulaire) qui en particulier contribue à l'activation de l'inflammasome, l'Ado possède un fort pouvoir immunosuppresseur qui est illustré chez les patients atteints d'une déficience de l'enzyme Adénosine Déaminase (ADA), ne pouvant dégrader l'Ado en Inosine (Ino), développent un Syndrome d'Immunodéficience Sévère. Contrairement au Treg murins, les Treg humains n'expriment pas CD73. Cependant nous avons pu identifier une population de lymphocytes T CD4+ mémoires non régulateurs (Tconv) exprimant CD73 et coopérant ainsi avec les Treg CD39+ pour la génération d'Ado. Cette population présente une capacité accrue de sécrétion de cytokines inflammatoires (IFNgamma, IL-17A, IL-22, GM-CSF) et l'expression de molécules (CXCR3, CCR6, MDR1) caractéristiques du profil Th1/17. De plus ces cellules semblent être moins sensibles à une régulation médiée par les points de contrôles dits immune-checkpoints (ICPs) tel que PD-1, CTLA-4, TIM-3, TIGIT. Par contre, les Tconv CD73+ sont sensibles à l'Ado généré lors de la coopération avec les Treg CD39+ qui engendre l'inhibition de leur prolifération et de leur sécrétion d'IFNgamma et de GM-CSF mais pas de l'IL-17A. L'Ado qui agit localement, peut également entrainer la suppression des Tconv CD73neg dans l'environnement proche. L'ensemble de ces résultats montre que l'expression de CD73 caractérise une population de T CD4 effecteurs polyfonctionnelle Th1/17 qui est une cible privilégiée et coopérative de l'immunosuppression des Treg dans l'environnement tumoral. En outre l'action d'Ado transforme ce puissant effecteur anti-tumoral en cellule potentiellement pro-tumorale via l'unique sécrétion privilégiée d'IL17 / Regulatory T cells (Tregs) play a key role in the immune system tolerance. In pathophysiology, a quantitative or functional defect in Treg promotes development of autoimmune diseases while their presence involved in tumor development. In particular, the presence of Treg in the immune stromal tumor environment (Ti-Treg) is associated with a poor prognosis for survival of patients suffering from breast cancer and ovarian cancer. Treg are recruited in the tumor through the CCL22 / CCR4 axis and are activated and amplified through their interaction with pDC expressing costimulatory axis ICOS-ICOSL and promoting their suppressive capacity. This project contributes to the efforts made in recent years to understand suppressive mechanisms of Treg operating in human tumors. Indeed, this project demonstrates that humans Ti-Treg strongly express the membrane ectonucleotidase CD39. This extracellular enzyme catabolizes Adenosine-triphosphate (ATP) to adenosine-monophosphate (AMP) which can then be degraded through the ectonucleotidase CD73 into Adenosine (Ado). While ATP is an Alarmine (extracellular danger signal) that particularly contributes to the inflammasome activation, Ado has strong immunosuppressive effect which is illustrated in patients with deficiency of the enzyme Adenosine Deaminase (ADA), which cannot degrade Ado into Inosine (Ino) and develop an Immunodeficiency Syndrome Severe. Unlike murine Treg, human Treg do not express CD73. However we could identify a non-regulatory population of CD4+ T cells (Tconv) expressing CD73, and thus cooperating with CD39+ Treg for Ado generation. This population has an increased capacity of secretion of inflammatory cytokines (IFNgamma, IL-17A, IL-22, GM-CSF) and the expression of molecules (CXCR3, CCR6, MDR1) characteristics of Th1/17 profile. Moreover, these cells appear to be less sensitive to regulation mediated by the immunocheckpoints (ICPs), such as PD-1, CTLA-4, TIM-3, TIGIT. Nonetheless CD73+ Tconv are sensitive to Ado generated in cooperation with CD39+ Treg which induce the inhibition of their proliferation and their secretion of IFNgamma and GM-CSF but not IL-17A . Ado acting locally, can also inhibit the Tconv CD73neg in the surrounding environment. All these results show that the expression of CD73 characterizes a population of multifunctional effector T CD4 Th1/17, which is a specific and cooperative target of Treg immunosuppression in the tumor environment. In addition the action of Ado transforms this potent anti-tumor effector to potentially pro-tumor cells which only secret IL17

Diabetes tipo 1 (DM1) e uma doenca autoimune que se inicia devido a defeitos na tolerancia imunologica a auto-antigenos, resultando na destruicao autoimune das celulas pancreaticas em individuos geneticamente suscetiveis. Os receptores NOD-like (NLRs) sao receptores intracelulares responsaveis pelo reconhecimento de padroes moleculares associados a patogenos (PAMPs) e padroes moleculares associados ao dano (DAMPs). Estudos recentes tem demonstrado que os receptores NOD1 e NOD2 desempenham um importante papel na ativacao da imunidade inata contra patogenos e na regulacao da imunidade adaptativa, uma vez que sua ativacao leva a producao de citocinas relacionadas a diferenciacao de linfocitos T auxiliares produtores de IL-17 (Th17). Porem, a importancia desses receptores no DM1 ainda e incerto. Nesse sentido, investigamos o papel dos receptores NOD1 e NOD2 na patogenese do DM1, com enfoque na diferenciacao de linfocitos Treg/Th17/Th1 e na plasticidade desses subtipos celulares. Nossos resultados mostram que camundongos deficientes de NOD2, mas nao NOD1 ou RIP2, sao resistentes ao DM1, como comprovado por menor incidencia, hiperglicemia, diminuicao do infiltrado inflamatorio e normalizacao dos niveis de insulina quando comparado aos controles. Foi observado tambem que animais NOD2-/- tiveram uma reducao da populacao de linfocitos Th17, Tc17, Th1 e T citotoxicos nos linfonodos pancreaticos, o que correlaciona com a inibicao da producao de IL-23p19 e IFN- no pancreas. Em paralelo, foi evidenciado o aumento do numero de celulas T reguladoras, macrofagos do perfil M2 nos linfonodos pancreaticos e elevada producao de IL-10 no pancreas de animais NOD2-/-. Alem disso, foi observado que animais NOD2-/- apresentaram uma menor populacao de linfocitos T duplo-positivos (Foxp3+RORt+ e IL-17+IFN+). Posteriormente, foi detectado menor producao de IL- 1, IL-6, IL-23p19 e IL-12p40 por celulas dendriticas de animais deficientes de NOD2. De forma interessante, foi observada a translocacao de bacterias para os linfonodos pancreaticos de animais diabeticos. Adicionalmente, animais tratados com antibioticos tornaram-se resistentes ao DM1, o que nos fornece indicios da contribuicao da microbiota intestinal na inducao da doenca. Por fim, comprovamos alta expressao genica de NOD2 nos linfonodos pancreaticos e no pancreas na fase inicial (pre-diabetica) em outro modelo de DM1, utilizando camundongos NOD (nonobese diabetic mice). Portanto, nossos dados indicam que a ativacao do receptor NOD2 por componentes bacterianos da microbiota intestinal induz a producao de citocinas pro-inflamatorias com subsequente diferenciacao/conversao de linfocitos do perfil Th17/Th1 e progressao do DM1. Dessa forma, estes dados apontam o bloqueio do receptor NOD2 como uma potencial terapia imunomoduladora para o DM1 em humanos. / Type 1 diabetes is an autoimmune disease that precipitates due to defects in the self tolerance to auto- antigens, resulting in the autoimmune destruction of the pancreatic cells in genetically susceptible individuals. NOD-like (NLRs) receptors are intracellular receptors responsible for the recognition of pathogen associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs). Recent studies have shown a role of NOD1 and NOD2 receptors in the innate immune response against pathogens and in the adaptive immune response, since its activation leads to the generation of cytokines related to the differentiation of IL-17-producing T helper cells (Th17). However, the role of these receptors in T1D remains elusive. Therefore, we investigated the role of NOD1 and NOD2 receptors in the pathogenesis of T1D, focusing on the differentiation of Treg/Th1/Th17 lymphocytes and in the plasticity of these subtypes. Our data demonstrate that NOD2-/- mice, but not NOD1-/- or RIP2-/-, are resistant to T1D, as shown by the lower incidence, hyperglycemia, less insulitis and normal insulin production when compared to wild type mice. It was also observed that NOD2-/- mice have a reduction in the Th17, Tc17, Th1 and cytotoxic T lymphocyte population within the pancreatic lymph nodes (PLNs), which correlates with the inhibition of IL-23p19 and IFN production in the pancreas. In parallel, there was an increase in Treg cells, M2 macrophages in the PLNs and IL-10 production in the pancreatic tissue of NOD2-/- mice. Also, NOD2-/- mice presented a downregulation of Foxp3+RORt+ and IL-17+IFN+ double-positive T cells. Later, it was shown that IL-1, IL-6, IL-23p19 and IL-12p40 production was downregulated in mice deficient to the NOD2 receptor. Interestingly, we observed a bacterial translocation to the pancreatic lymph nodes in diabetic mice, what could be triggering NOD2 activation, thus contributing to T1D development. As expected, mice pre-treated with antibiotics failed to become diabetic, suggesting a possible role of the gut microbiota in the development of the disease. Lastly, we observed a higher relative expression of NOD2 in the PLNs and pancreas of pre-diabetic mice, using another mouse model of the disease, the nonobese diabetic (NOD) mouse. Collectively, our data suggest that components from the gut microbiota are capable of translocating to the PLNs, thus triggering the activation of NOD2, which in turn induces the production of proinflammatory cytokines related to the differentiation of Th1/Th17 cells, thus contributing to T1D development in a mouse model of the disease. Therefore, the blockade of NOD2 appears as an interesting therapeutical target in the treatment of type 1 diabetes in humans.

Made available in DSpace on 2015-05-14T12:59:59Z (GMT). No. of bitstreams: 1 arquivototal.pdf: 2254071 bytes, checksum: 5ef1f814625ed46426cc35ec211b8399 (MD5) Previous issue date: 2013-03-27 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES / Root bark infusions of the plant Cissampelos sympodialis Eichl (Menispermaceae) are used in folk medicine, in Northeast Brazil, for the treatment of diseases of the respiratory and digestive tracts. Previous studies showed that the hydroalcoholic extract of the leaves (AFL) of the plant and warifteine (W), alkaloid bisbenzylisoquinolinic, presented anti-inflammatory and anti-allergic effects. This study evaluated the effect of the oral treatment of mice with W and methyl warifteine (MW) in the paw edema formation induced by phlogistic agents, vascular leakage and cell migration in acute inflammatory models and the effect of oral treatment with AFL and its alkaloids (W and MW) in chronic inflammation represented by the experimental model of food allergy (BALB / c mice sensitized with ovalbumin - OVA). Oral treatment with W reduced the paw edema induced by carrageenan, histamine and prostaglandin E2, an effect not presented in MW treatment. The warifteine and methyl-warifteine also reduced the vascular leakage, however without inhibiting cell migration associated with inflammation. In the experimental model of food allergy the treatment with W induced weight gain in animals with decreased of diarrhea. Methylation of warifteine did not induce weight gain nor inhibited allergic diarrhea during the allergen challenge. However treatment with AFL did not induce weight gain nor inhibited allergic diarrhea. In contrast, treatment with the AFL or its alkaloids reduced the IgE specific for ovalbumin (OVA) titer, increased the proportion of CD4 + or CD8+ T lymphocytes in mesenteric lymph nodes. The proportion of regulatory T lymphocytes in the mesenteric lymph nodes was also increased by the treatments. In vitro experiments, with cells from mesenteric lymph nodes of sensitized animals, demonstrated that W and MW inhibited the secretion of interleukin (IL-) 12 and IL-10 with no change in the interferon-γ (IFN-γ) and IL- 13 levels. These results demonstrated that the oral treatment with warifteine presented anti-inflammatory activity by inhibiting the action of mediators of inflammation and the methylation of the molecule did not improve this effect. Also, the treatment with AFL, W and MW showed immunomodulatory effects in food allergy with increased of Treg cells and decreased of cytokines derived from cells of the innate immune mechanism independent of that of the adaptive immune mechanism. / Infusões das raízes da planta Cissampelos sympodialis Eichl (Menispermaceae) são utilizadas, pela medicina popular, no Nordeste Brasileiro, para o tratamento de doenças do trato respiratório e digestório. Estudos prévios demonstram que o extrato hidroalcoólico das folhas (AFL) da planta e a warifteina (W), alcaloide bisbenzilisoquinolínico, apresentam efeitos anti-inflamatórios e antialérgicos. Esse estudo avaliou, portanto, o efeito do tratamento oral de camundongos com W e a metil-warifteina (MW) na formação do edema de pata induzido por agentes flogísticos, no extravasamento vascular e na migração celular em modelos de inflamação aguda e o efeito do tratamento oral com a AFL e seus alcaloides (W e MW) na inflamação crônica representada pelo modelo experimental de alergia alimentar (camundongos BALB/c sensibilizados com ovalbumina - OVA). O tratamento com a W reduziu o edema de pata induzido por carragenina, por histamina ou prostaglandina E2, efeito esse não observado com o tratamento com MW. A warifteina e a metil-warifteina também reduziram o extravasamento vascular, contudo sem inibir a migração celular associada à inflamação. No modelo experimental de alergia alimentar o tratamento com W induziu ganho de peso dos animais com diminuição da diarreia. A metilação da warifteina, embora não tenha induzido o ganho de peso diminuiu a diarreia durante os desafios com o alérgeno. Todavia o tratamento com AFL não induziu o ganho de peso e nem inibiu a diarreia alérgica. Diferentemente, os tratamentos com o AFL e com os alcaloides reduziram os títulos de IgE específica para ovalbumina (OVA), aumentaram a proporção de linfócitos T CD4+ e CD8+ no linfonodo mesentérico. A proporção de linfócitos T reguladores foi aumentada no linfonodo mesentérico pelos tratamentos em estudo. Os experimentos in vitro, com células do linfonodo mesentérico de animais sensibilizados, demonstraram que W e MW inibiram a secreção de interleucina (IL-)12 e IL-10, sem alteração nos níveis de interferon-γ (IFN-γ) e IL-13. Esses resultados demonstraram que o tratamento oral com warifteina apresentou atividade anti-inflamatória por inibir a ação de mediadores da inflamação e que a metilação da molécula não potencializou seu efeito. Também, os tratamentos com AFL, W e MW apresentaram efeitos imunomoduladores na alergia alimentar com aumento de células Treg e com diminuição de citocinas oriundas de células do mecanismo imune inato independente das do mecanismo imune adaptativo.